Bragar Eagel & Squire, P.C. is encouraging investors who experienced significant losses in Charming Medical Limited (NASDAQ: MCTA) to contact the firm before the February 17, 2026, deadline to serve as lead plaintiffs in a class action lawsuit. The litigation alleges that the company failed to disclose an undisclosed stock promotion scheme that leveraged social media misinformation and impersonated financial professionals to drive investor interest.
The stock experienced a dramatic price surge, climbing from $4.00 to $29.36 between October 10 and November 12, 2025, before the Securities and Exchange Commission halted trading in the security. The timing of the trading halt followed the alleged fraudulent promotion activities, raising questions about the disclosure controls in place during the rapid appreciation period.
Investors who purchased MCTA shares during the specified timeframe and sustained losses are eligible to apply for lead plaintiff status in the litigation. The February 17, 2026, deadline represents a critical cutoff date for investors seeking to participate in the action or assume a leadership role in the proceedings. Lead plaintiffs typically work closely with legal counsel to represent the broader class of affected shareholders.